Savella
Indicated to manage central nervous system signaling to alleviate physical pain in fibromyalgia.
- Category
- Antidepressants
- Active ingredient
- Milnacipran
- Supply
- Pharmacy
- Route
- Oral use
- Form
- Film-coated tablet
- Strengths
- 25mg
Savella details
- Condition
- Fibromyalgia
- Therapeutic class
- Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
- Pharmacological class
- SNRI
- Minor side effects
- nausea; headache; constipation; dizziness
- Moderate side effects
- palpitations; hypertension; insomnia
- Dosage forms
- Film-coated tablet
- Administration route
- Oral use
- Supply category
- Pharmacist only, dispensed without a prescription
- Manufacturer
- Allergan
- Onset Time
- 2–4 weeks
- Duration
- 12–24 hours
- Storage instructions
- Store in a dry location at controlled temperature.
- Drug interactions
- MAO inhibitors; aspirin; NSAIDs
- Age restrictions
- Not established for use in children.
- Pregnancy and breastfeeding
- Pregnancy: Avoid unless necessary. Breastfeeding: Not recommended.
Contraindications
hypersensitivity to milnacipran; narrow-angle glaucoma; concurrent use of MAO inhibitors
Precautions and warnings
monitor blood pressure and heart rate; use with care in patients with seizure disorders; observe for signs of suicidal thinking
Serious side effects
serotonin syndrome, requires immediate medical attention; suicidal ideation, requires immediate medical attention
Patient summary
indicated to manage central nervous system signaling to alleviate physical pain in fibromyalgia.
Mechanism of action
This medication functions as a neurotransmitter modulator. By inhibiting the reuptake of both norepinephrine and serotonin, it increases the availability of these chemicals in the synapse, which helps in modulating pain pathways.
Where this medicine is registered
- Singapore
- Hong Kong
- Thailand
- Malaysia
- Philippines
- Indonesia
- Taiwan
- South Korea
- Japan
- Australia
- New Zealand
- UAE
- South Africa
About Savella
Savella contains the active ingredient milnacipran, used to manage the symptoms of fibromyalgia. Produced by Allergan, the medication is provided as a tablet in 25mg strength. It serves as a targeted option for patients seeking to alleviate the chronic pain and physical exhaustion that typically characterise this condition.
Savella availability in Asia
Savella is registered across 13 markets including Indonesia, Taiwan and South Korea, with availability also in Japan, the UAE and Singapore. Access to consistent medical care is important for those managing fibromyalgia while overseas. Because of the nature of milnacipran, this medication is best used under the ongoing guidance of a doctor to monitor its influence on the condition.